:max_bytes(150000):strip_icc()/GettyImages-2126120522-730a9ed46abd4e5195fa2b13a1269d84.jpg)
Quick Dispatch:
Your tirzepatide surmount 1 SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surmount 1 SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes ships.
Need Help?
Questions about tirzepatide surmount 1 SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surmount 1 SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes in your area.
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh
22.82
A 3-year study of tirzepatide in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1
20.66
01200-X/asset/a888810c-3ccf-4f48-b252-0dfdf720d276/main.assets/gr3_lrg.jpg)
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
20.10
Weight reduction with different doses of Tirzepatide in Surmount 1
24.50
SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients
29.42
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
22.08
SURMOUNT-1
23.90
